TCR-independent CD137 (4–1BB) signaling promotes CD8(+)-exhausted T cell proliferation and terminal differentiation

CD137 (4–1BB)-activating receptor represents a promising cancer immunotherapeutic target. Yet, the cellular program driven by CD137 and its role in cancer immune surveillance remain unresolved. Using T cell-specific deletion and agonist antibodies, we found that CD137 modulates tumor infiltration of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pichler, Andrea C., Carrié, Nadège, Cuisinier, Marine, Ghazali, Samira, Voisin, Allison, Axisa, Pierre-Paul, Tosolini, Marie, Mazzotti, Céline, Golec, Dominic P., Maheo, Sabrina, do Souto, Laura, Ekren, Rüçhan, Blanquart, Eve, Lemaitre, Lea, Feliu, Virginie, Joubert, Marie-Véronique, Cannons, Jennifer L., Guillerey, Camille, Avet-Loiseau, Hervé, Watts, Tania H., Salomon, Benoit L., Joffre, Olivier, Grinberg-Bleyer, Yenkel, Schwartzberg, Pamela L., Lucca, Liliana E., Martinet, Ludovic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649891/
https://www.ncbi.nlm.nih.gov/pubmed/37392737
http://dx.doi.org/10.1016/j.immuni.2023.06.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649891/
https://www.ncbi.nlm.nih.gov/pubmed/37392737
http://dx.doi.org/10.1016/j.immuni.2023.06.007

Ejemplares similares